Unicycive Therapeutics (UNCY) Consolidated Net Income (2020 - 2026)
Unicycive Therapeutics (UNCY) reported Consolidated Net Income of -$8.0 million for Q1 2026, down 3.41% on a YoY basis from -$8.3 million in Q1 2025, and down 16.57% quarter-over-quarter from -$6.9 million in Q4 2025.
Unicycive Therapeutics (UNCY) Consolidated Net Income (2020 - 2026) Analysis & Trends
Unicycive Therapeutics has reported Consolidated Net Income for 7 years, with the latest figure at -$8.0 million in Q1 2026.
- For the quarter ending Q1 2026, Consolidated Net Income fell 3.41% year-over-year to -$8.0 million; the trailing twelve-month figure through Mar 2026 stood at -$28.8 million (up 2.4% YoY), and the FY2025 full-year result was -$28.6 million, up 7.6% from the prior year.
- Consolidated Net Income for Q1 2026 stood at -$8.0 million, down from -$6.9 million in the prior quarter.
- The five-year high for Consolidated Net Income was -$3.5 million in Q1 2022, with the low at -$9.2 million in Q1 2024.
- Historically, Consolidated Net Income has averaged -$6.2 million across 5 years, with a median of -$6.2 million in 2023.
- Annual changes were most pronounced in 2022 — Consolidated Net Income tumbled 259.82% — and 2025, when it rose 23.05%.
- Unicycive Therapeutics' Consolidated Net Income stood at -$5.3 million in 2022, then declined by 16.22% to -$6.2 million in 2023, then plunged by 44.82% to -$9.0 million in 2024, then climbed by 23.05% to -$6.9 million in 2025, then declined by 16.57% to -$8.0 million in 2026.
- The last three Consolidated Net Income figures came in at -$8.0 million (Q1 2026), -$6.9 million (Q4 2025), and -$7.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Unicycive Therapeutics | 174.05 Mn | 119.47 Mn | - | -8.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.04 Mn |
| Dec 31, 2025 | -6.90 Mn |
| Sep 30, 2025 | -7.08 Mn |
| Jun 30, 2025 | -6.82 Mn |
| Mar 31, 2025 | -7.78 Mn |
| Dec 31, 2024 | -8.97 Mn |
| Sep 30, 2024 | -5.85 Mn |
| Jun 30, 2024 | -6.96 Mn |
| Mar 31, 2024 | -9.16 Mn |
| Dec 31, 2023 | -6.19 Mn |
| Sep 30, 2023 | -5.73 Mn |
| Jun 30, 2023 | -4.12 Mn |
| Mar 31, 2023 | -4.20 Mn |
| Dec 31, 2022 | -5.33 Mn |
| Sep 30, 2022 | -5.56 Mn |
| Jun 30, 2022 | -3.64 Mn |
| Mar 31, 2022 | -3.54 Mn |
| Dec 31, 2021 | -2.75 Mn |
| Sep 30, 2021 | -4.77 Mn |
| Jun 30, 2021 | -1.10 Mn |